Dr Reddy’s Buys Italian Firm Generici Sri
This article was originally published in PharmAsia News
Executive Summary
India's Dr Reddy's announced it has bought an Italian generics maker, Generici Sri, but did not disclose the purchase price. The announcement came close on the heels of another foreign buy by Indian company Dowpharma's United Kingdom divisions. The acquisition increases Dr Reddy's stake in the Italian pharmaceutical market judged to be worth $893.5 million, the third largest in Europe. Generici's pipeline is expected to supplement Dr Reddy's own. (Click here for more
You may also be interested in...
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths
Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.